Earnings call
Aurobindo Pharma Q3 FY25 earnings call: Aurobindo Pharma Limited expects to break even by March 2025
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects to break even by March 2025. The company has a present formulations annual manufacturing capacity of 50 billion+ units and intends to increase it further to drive future growth. The company achieved its highest-ever quarterly revenue of ₹7,979 crores in Q3 FY25, with year-on-year and quarter-on-quarter growth. The company had 11% market share and believes there is scope to grow, given its background and infrastructure in India. As of December 31st, 2024, Aurobindo Pharma Limited had 226 Specialty & Injectables ANDA filings, with 170 final approvals and 56 under review.
The numbers management gave
Results
- The company achieved its highest-ever quarterly revenue of ₹7,979 crores in Q3 FY25, with year-on-year and quarter-on-quarter growth.
Show source
This quarter, we have achieved our highest ever quarterly revenues reaching ₹7,979 crores with a remarkable growth both year-on-year and quarter-on-quarter.
- Gross contribution was ₹4,663 crores in Q3 FY25, its highest level.
Show source
2 Aurobindo Pharma Limited 07 February 2025 Gross contribution also stood at highest level at ₹4,663 crores.
- Gross margin was 58.4% in Q3 FY25, up 130 bps year-on-year despite low transient sales, owing to benign raw material prices.
Show source
Gross margins remained at 58.4% increased by 130 bps year-on-year despite low transient sales , owing to benign raw material prices.
- EBITDA was ₹1,628 crores, with a margin of 20.4%, in Q3 FY25, after absorbing around ₹50 crores more R&D cost than in Q3FY24 due to its strategic focus on developing complex products, including specialty and biosimilars.
Show source
Our EBITDA stood at ₹1,628 crores with a healthy margin of 20.4% even after absorbing higher R&D cost of around ₹50 crores over Q3FY24 given our strategic focus on development of complex products including specialty and biosimilars.
- EBITDA before R&D was 25.8%, or ₹2,056 crore, in Q3 FY25, against ₹1,975 crores in Q3FY24.
Show source
EBITDA before R&D stood at 25.8% or ₹2,056 crore against ₹1,975 crores in Q3FY24.
- Net debt fell to US$84 million in Q3 FY25 as cash flows improved significantly through strong working capital management.
Show source
Our cash flows improved significantly on the backdrop of a strong working capital management leading to a reduction in net debt to US$84 million.
Show 29 more statements
Results
- Formulations business grew 11% year-on-year to ₹6,973 crores in Q3FY25, contributing approximately 87% of total revenues.
Show source
Formulations Business: In Q3FY25, our formulations business witnessed a robust year-on- year growth of 11% to ₹6,973 crores, contributing approximately 87% of the total revenues.
- API business recorded revenue of 1,006 crores in Q3 FY25.
Show source
The API business recorded a revenue 1,006 crores.
- U.S. formulations business recorded revenue of US$435 million in Q3 FY25, against US$421 million in Q2FY25, reflecting quarter-on-quarter growth.
Show source
USA: During the quarter, our U .S. formulation s business recorded revenues of US$435 million against US$421 million in Q2FY25, reflecting a strong quarter-on-quarter growth.
- Overall generic products revenue in the USA increased 4% year-on-year to US$297 million in Q3 FY25, driven by volume gains and new product launches.
Show source
Revenue from overall generic products in USA increased by 4% year -on-year to US$297 million driven by volume gains and new product launches.
- Specialty & Injectables business in the US recorded US$76 million in Q3 FY25, mainly due to low transient business sales and Christmas-related cut-off issues.
Show source
The Specialty & Injectables business in US remained at US$76 million mainly due to low transient business sales and cut- off related issues due to the Christmas.
- The company filed 4 ANDAs, received final approval for 8, and launched 7 products during Q3 FY25.
Show source
During the quarter, we filed 4 ANDAs, received final approval for 8, and launched 7 products.
- Europe formulations business recorded revenue of ₹2,121 crores in Q3 FY25, up 23% year-on-year.
Show source
Europe: Our Europe formulations business continues to deliver strong results, registering a revenue of ₹2,121 crores, a significant growth 23% year-on-year.
- Europe formulations business revenue in constant currency was €236 million in Q3 FY25, against €229 million in Q2FY25.
Show source
In constant currency terms, our revenue stood at €236 million against €229 million in Q2FY25.
- Growth markets revenue increased 39% year-on-year to ₹873 crores or US$104 million in Q3 FY25, driven by geographical expansion and strong sales momentum.
Show source
Growth Markets: Revenue from the growth markets saw a remarkable 39% year-on-year increase reaching ₹873 crores or US$104 million driven by our successful geographical expansion and strong sales momentum.
- ARV business stood at US$36 million [₹307 crores] in Q3 FY25.
Show source
3 Aurobindo Pharma Limited 07 February 2025 ARV: The ARV business stood at US$36 million [₹307 crores].
- Gross margin was 58.4% in Q3 FY25, against 57.1% in the previous year, with benign raw material costs supporting the margin.
Show source
Now, going to the other highlights - The raw material costs continued to be at benign levels supporting our gross margin, which stood at 58.4% against 57.1% of previous year.
- Average finance cost was 5.6% in Q3 FY25.
Show source
The average finance cost for the quarter was 5.6%.
- Average USD-INR exchange for Q3 FY25 was 84.46, against 83.76 in Q2FY25.
Show source
The average USD-INR exchange [for the quarter] is at 84.46 against 83.76 in Q2FY25.
- The company had around ₹60 crore operational loss at its Pen-G plant for the quarter; the plant had completed a small shutdown to include or modify equipment and restarted 10 days ago.
Show source
S. Subramanian: We had around ₹60 crore operational loss and the plant has gone for a small shutdown for including/modifying some of the equipment which has completed, and we started it 10 days back.
- The company has announced positive Phase 1 results with Omalizumab versus the European and U.S. innovator product.
Show source
We already announced positive Phase 1 results with Omalizumab versus the European and the U.S. innovator product, I think last year.
- Eugia business was impacted by around US$10 million per quarter in each of the last two quarters mainly because of supply-related issues, not demand challenges; the company expects to be back to its normal run rate from this quarter onwards.
Show source
Yugandhar Puvvala: Yeah, I think I already clarified that, like last two quarters have been mainly related to supply related issues and, per quarter we were impacted by around US$10 million and I expect from this quarter onwards we'll be back to normal run rate.
- Europe contributed close to 27% of Aurobindo Pharma’s global revenues in the third quarter and nine months period ended December 31, 2024.
Show source
Yes, Europe has been contributing close to 27% of the global revenues for Aurobindo.
- Eugia grew at a rate of 20% in Europe.
Show source
Yugandhar Puvvala: Just to add like there can be supply challenges from a lot of companies and we are in a position to, take in fact like even Eugia has been growing at a rate of 20% in Europe.
- Eugia-3 was using around 50% of its existing capacity, compared with around 70%-75% in the past; Aurobindo Pharma is confident it will return to 65%-70% capacity utilization of the previous capacity.
Show source
Right now, we were using around 50%, so like we are confident that we will come back to our original levels of 65 %-70% capacity utilization of the previous capacity.
- Net profit for Q3FY25 was ₹ 846 Cr.
Show source
Our net profit for the quarter stood at ₹846 crores.
- API business faced continued pricing pressures, partly offset by volume gains and improved asset utilization in Q3 FY25.
Show source
While pricing pressures continued, these were partly offset by the volume gains and improved asset utilization.
- Price erosion on an overall basis in the U.S. was neutral in Q3 FY25, supported by its well-diversified portfolio.
Show source
The price erosion on overall basis remained neutral supported by our well diversified portfolio.
- Injectable business is ramping up slowly because of production problems, and the company is not in a position to meet demand despite very high customer interest and contracts in place; it does not want to rush production just to meet demand.
Show source
Anubhav, I can tell you that with full confidence, it is that we are ramping up slowly and we don't want to rush anything and all our contracts and interest from the customers is very, very high and we are not in a position to meet the demand, but I do not want to rush anything just to meet the demand.
- Europe formulations business growth in Q3 FY25 was driven by performance across all key European geographies. Replaced by a later filing.
Show source
This growth was driven by robust performance across all key European geographies.
- ARV business growth was driven by additional opportunities in Q3 FY25. Replaced by a later filing.
Show source
The growth in ARV business was driven by additional opportunities.
- The company is clocking better margins in Europe as it continually looks at sales opportunities. Replaced by a later filing.
Show source
Yeah, I mean on the margin side as well as we are very constantly looking at the opportunity sales to be availed, definitely we are clocking better margins .
Money and capital
- Net Capex was around US$106 million in Q3 FY25.
Show source
Net Capex for the quarter is around US$106 million.
- Business had a net cash inflow of US$49 million in Q3 FY25, supported by an improved working capital position.
Show source
The business had a net cash inflow of US$49 million during the quarter.
- Net debt after investments improved to US$84 million at the end of December from US$133 million in September 24.
Show source
As a result, the net debt after investments at the end of December improved to US$84 million from US$133 million in September 24.
What it expects ahead
What management expects
- The company expects to break even by March 2025.
Show source
We expect to break even by March 2025.
- The company is scaling up production mainly from Eugia-3 and has completed all remedial actions; from this quarter onwards, it will reach its previous capacity utilization of around 60% to 70%, compared with around 50% currently.
Show source
Yugandhar Puvvala: Hi, so as you rightly said, it is basically like we are scaling up the production mainly from Eugia-3 and we have completed all the remedial actions and this quarter onwards, we will be reaching to our original what we used to do, which is around 60 to 70% of capacity utilisation.
- Bevacizumab clinical study has been ongoing for about 3 years and is nearing closure; the company expects to conclude recruitment in two quarters and probably file in Q1-Q2 of FY26-27.
Show source
I think in two quarters time we will conclude the recruitment phase and probably we will have a filing in Q1 -Q2 of the next fiscal, which means (in) FY26 -27 for Bevacizumab, but with the MHRA approval that we received for the Bevacizumab, we are talking to a few regulatory agencies in the emerging and the semi -regulated markets where we can position the dossier based on the MHRA approval alone.
- The company expects to have at least six to seven products in the European and semi-regulated markets by 2026, supported by approvals received or positive opinions received; the ophthalmic product is excluded from the pipeline advancing fairly well.
Show source
So, in the nutshell, except for the ophthalmic product, the pipeline is advancing fairly well and with approvals that we have received or the positive opinions that we have received, we are quite confident by 2026, we will be able to at least have six to seven products in the European and the semi-regulated markets.
- The company expects its biosimilar business to reach the inflection point in 2028 to 2030.
Show source
As I told you, 2028 to 2030 will be the inflection point of this business.
- The company has 3 approved products, 2 with a positive opinion in Europe and 1 in UK, and expects one more this year; with Denosumab, Omalizumab, and one more in the next year, it expects at least 7 products to be commercialized fully by the year 2027 (28).
Show source
You can already see that we have 3 products which are approved, 2 with a positive opinion in Europe, 1 in UK, and we are expecting one more this year and with Denosumab, Omalizumab, and one more 10 Aurobindo Pharma Limited 07 February 2025 in the next year, we expect at least 7 products to be commercialized fully by the year 2027 (28).
Show 12 more statements
What management expects
- The company expects to build a good revenue base in 2028 to 2030, when the company takes off by itself.
Show source
And [by] 2028 to 2030, will build in a good revenue base for us, where I think the company takes off by itself.
- The company is on track to achieve its internal target of 21-22% EBITDA margin for the full year, with the second half expected to be better than the first half.
Show source
We are on track to achieve our internal EBITDA margin target of 21% to 22% for FY25.
- The company expects its net debt to improve further by the end of fiscal year FY25.
Show source
We expect the net debt to improve further by the end of the fiscal year FY25.
- Backward integration efforts are expected to improve operational efficiencies and contribute strongly to financial performance in FY26, offsetting the anticipated decline in transient sales and strengthening and sustaining revenue and profitability.
Show source
Our backward integration efforts are expected to drive enhanced operational efficiencies and deliver strong contribution to our financial performance in FY26, which not only offsets the anticipated decline in transient sales but also strengthen and sustain our revenue and profitability growing forward.
- The company expects its efforts to optimize the working capital cycle to enhance its balance sheet and improve cash flows.
Show source
At the same time, our proactive efforts to optimize the working capital cycle will further enhance our balance sheet and improve cash flows, reinforcing our financial stability and long-term growth potentials.
- The company expects Q4FY25 to be strong, driven by increased transient sales, execution of strategic initiatives and improved operational efficiencies.
Show source
The next quarter [Q4FY25] is expected to be strong and driven by increased transient sale s, execution of strategic initiatives and improved operational efficienc ies.
- The company expects capacity utilization to return to previous levels from this quarter onwards and does not expect any further decline from here on.
Show source
So, I expect this quarter onwards, we should go back to the previous levels, and I don't expect any further decline happening from here on.
- The company expects to conclude the Omalizumab clinical study by the end of this year.
Show source
But I'm quietly confident that by the end of this year, the Omalizumab clinical study will be concluded as well.
- The company considers Q4 filing for Omalizumab, at least in Europe, a possibility in the next fiscal.
Show source
So, we are quite confident of closing out the Omalizumab clinical study by the end of the year, and Q4 filing, at least in Europe, still looks a possibility in the next fiscal.
- The company expects its injectable business to be much better in Q4 and Q1 of next year.
Show source
I expect Q4 and Q1 of next year to be much better, but in terms of customer interest and all the contracts very much in place, absolutely no issue s. Anubhav Agarwal: And on the utilization, the reason utilization is low because CAPA progress is happening, does the facility still have lot of consultants over there?
- The company expects growth momentum in Europe and other key markets to sustain, further accelerating its revenue stream. Replaced by a later filing.
Show source
The growth momentum in Europe and other key market is expected to sustain, further accelerating our revenue stream.
- The company is willing to take on more volume for the U.S. market. Replaced by a later filing.
Show source
We are happy to take on more volumes.
What it is building and selling
Projects and capacity
- The company has a present formulations annual manufacturing capacity of 50 billion+ units and intends to increase it further to drive future growth.
Show source
Strategic Initiatives: Expanding our manufacturing capacities: We have a present formulations annual manufacturing capacity of 50 billion+ units.
- The company commercialized its China plant, with an annual OSD capacity of around 2 billion units that is expandable further over the near to medium term; the plant is expected to contribute to revenues in FY26.
Show source
We have commercialized our China plant with an annual OSD [manufacturing capacity] of around 2 billion units, which is expandable further over near to medium term.
- Denosumab biosimilar to Xgeva and Prolia is being tested in post-menopausal osteoporosis; the company is on track to conclude the clinical study by May 2025, expects the clinical study report by September 2025, expects European filing in the October quarter and U.S. filing in Q4 of FY26.
Show source
We are on track to conclude the clinical study by May this year [2025], which means that we will have the clinical study report available with us by September [2025], and I hope to, if there are no further delays in gleaning the data, because this trial was completely conducted in 8 European countries and 65 sites, I expect the European filing to be in the October quarter and the U.S. filing to be in the Q4 of the next fiscal [FY26].
- The company expects to conclude the Phase 3 clinical trial for its ophthalmic product in the second half of 2026; recruitment is around 50% complete, and the company does not think it will complete recruitment in 2025 as estimated before.
Show source
I think we will be well into the second half of 2026 when we (will) conclude the Phase 3 clinical trial for the ophthalmic product.
- The company expects Eugia-3 and the Vizag facility to provide significant capacity for the business and its growth plans up to FY30.
Show source
So, between Eugia-3 and Vizag facility, we will have significant capacity to take care up to FY30 in terms of the capacity available for the business and our business growth plans.
- The company expects its US based OSD plant at Dayton to be commercialized in the next fiscal year.
Show source
We expect our US based OSD plant at Dayton to be commercialized in the next fiscal year.
Show 12 more statements
Projects and capacity
- The company expects its Raleigh plant, currently manufacturing topical products, to be fully operational next fiscal year to include transdermal and respiratory products.
Show source
Our other plant in Raleigh, which is currently manufacturing topical is expected to be fully operational next fiscal year to include transdermal and respiratory products.
- The company is witnessing good yield improvements in the capacity ramp-up process at its strategic Pen-G and forward derivatives investments, which are on track.
Show source
Our backward integration: We are witnessing good yield improvements in the capacity ramp up process in our strategic investments n amely, the Pen-G and forward derivatives is on track.
- Omalizumab biosimilar to Xolair is being tested in chronic spontaneous urticaria across European sites in Caucasian patients; patient recruitment is delayed by about four to five months, partly made up by adding sites in India, leaving a three-month delay in closing the study.
Show source
I think I talked about it last quarter, but what is important to note is, we made -up for a couple of months by increasing the number of sites in India, earlier India was not part of the recruitment plans which means that I'll still have a delay of three months in closing out the study.
- At Aurobindo Pharma’s Vizag facility, approvals have been received for terminally sterile lines; the company will seek approval for aseptic lines after an audit that is due, and will add cartridge lines exclusive to Vizag as well as PFS and BFS lines.
Show source
Now, we will be going for the aseptic lines approval that audit is due and then we will be adding different varieties of things in Vizag, the cartridge lines will be all exclusive only for Vizag and there is a PFS, BFS all those lines what we will be adding.
Demand and pricing
- The company had 11% market share and believes there is scope to grow, given its background and infrastructure in India.
Show source
We are today 11% market share.
Segments
- As of December 31st, 2024, Aurobindo Pharma Limited had 226 Specialty & Injectables ANDA filings, with 170 final approvals and 56 under review.
Show source
As of December 31st, 2024, we have a total of 226 Specialty & Injectables ANDA filings with 170 having final approvals and 56 under review.
- The company has four more products in Phase 3 clinical trial.
Show source
As I told you, I think last quarter the biosimilar to Xgeva and Prolia, which is a Denosumab biosimilar being tested in post-menopausal osteoporosis.
- European business is supported by its wide product portfolio, efficient supply chain, increased supplies originating mainly from India, faster product turnaround at its quality lab mainly at Malta, and commercial infrastructure.
Show source
Currently, we are doing this based on the wide portfolio of the products and efficient supply chain and increased supplies originating mainly from India and faster turnaround of the products at our quality lab, mainly at Malta.
- Domestic sales of Trastuzumab will be through co-marketing partners for the first two quarters, until its domestic marketing and sales team, which is being put together, probably kicks in by the end of this year; going forward, the company is going to add a sales team in the domestic market to take its biosimilars to patients and prescribers.
Show source
We are putting together our domestic marketing and sales team, which will kick in probably by the end of this year, but until then, the first two quarters the sales will be through co -marketing partners.
- The company is having a separate sales team for biosimilars because the team specializes in branding them and requires a network to present biosimilars convincingly to prescribers.
Show source
Dr. Satakarni Makkapati: For the biosimilars, we are having a separate sales team because they specialize in branding it, and importantly, there is a lot of network that is required to put forward biosimilars to the prescribers convincingly.
- The company has enough freedom to scout for products and in-license them when and if required, and is open to in-licensing opportunities for products that would significantly add to its commercial base in regulated or semi-regulated markets. Replaced by a later filing.
Show source
There is enough freedom to go out and scout for products and in-license them when and if required, Anubhav, but right now, we covered most of the important products that we think will position us both in Oncology, Dermatology, and the Immunology segments, so Dermatology is part of Immunology.
Deals and partners
- The company partnered with a global pharma major for development of a respiratory product.
Show source
Recently, we have partnered with a global pharma major for development of respiratory product, highlighting our commitment towards the complex portfolio.
Risks, rules and outside factors
Rules and policy
- The company says regulatory agencies' approaches to approving a product based only on Phase 1 and the process for approval remain dynamic.
Show source
It's still very dyn amic in the 8 Aurobindo Pharma Limited 07 February 2025 way regulatory agencies look at how the product gets approved only based on Phase 1 and what is the process forward in approving it.
- The company has an approval by the CDSCO for Trastuzumab.
Show source
So, we have an approval by the CDSCO for Trastuzumab.
- The company will provide information if it receives approvals in emerging markets or semi-regulated markets. Replaced by a later filing.
Show source
So, if there are any approvals that I receive in emerging markets or semi-regulated markets, I'll let you know.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Tushar Manudhane: Yeah. Good morning, Sir. Just on Pen -G, to start with , like what kind of operational loss currently we have for the quarter?
Answer, s subramanian
S. Subramanian: We had around ₹60 crore operational loss and the plant has gone for a small shutdown for including/modifying some of the equipment which has completed, and we started it 10 days back.
Question
Tushar Manudhane: And what kind of pricing outlook are we sort of building once we break even or let's say for the external sales?
Answer, s subramanian
S. Subramanian: Current pricing of Pen -G is around US$26. However, we are not depending on the Pen-G sales alone. We have created capacities across the value chain of Pen-G, so we 5 Aurobindo Pharma Limited 07 February 2025 will be able to supply it as Pen-G or 6-APA or Amoxicillin etc. So we will be able to manage it even if the price goes down and we may even do better.
Question
Tushar Manudhane: Understood. And secondly in terms of the raw material prices, what's the outlook whether do you see the inventory in this industry itself lowering down, so that will benefit in terms of raw material prices for us going forward?
Answer, s subramanian
S. Subramanian: I think the current raw material prices continue to be there [at current levels] and what will happen because of the inventory going down is a very futuristic question, but I think, at any point of time, we will be having around three to six months tops, so may not be a big issue in our view.
Question
Tushar Manudhane: And lastly on Eugia, when do we see the production scaling up or let's say the sales scaling up, we've seen now like second quarter where sales been really trending downwards?
Answer, yugandhar puvvala
Yugandhar Puvvala: Hi, so as you rightly said, it is basically like we are scaling up the production mainly from Eugia-3 and we have completed all the remedial actions and this quarter onwards, we will be reaching to our original what we used to do, which is around 60 to 70% of capacity utilisation. Right now, we are still doing around 50% capacity utilization. So, I expect this quarter onwards, we should go back to the previous levels, and I don't expect any further decline happening from here on.
Question
Kunal Randeria: Good morning, Sir. So, my question is around your plans in China? So how should we look at this market shaping up because in the past you and several of peers have spoken of this opportunity, but I don't think there has been any material contribution yet. So, just wondering if you can share some details, the kind of products you have, the time it takes to get approval, the reimbursement process, the launch pipeline you have, and the revenue projection for the next two to three years?
Answer, s subramanian
S. Subramanian: Yeah, Kunal, we started our China plant in the last week of November, and it is in the ramping up process. The China plant will start billing sometime in the month of April, mainly to the European markets. We also have certain approvals for China and also we already got the European approval, so we can supply to Europe. China, we are in the process of getting it and after that there may be an inspection for U.S. also. So, in the next year, it will ramp up fully and probably in another two to three years, we will see good traction coming out of the China plant.
Question
Kunal Randeria: And the kind of products and just curious, why would you be, not trying to supply more to the Chinese market? 6 Aurobindo Pharma Limited 07 February 2025 S. Subramanian: No, immediately we are having the European approval, so will supply to Europe.
Answer, s subramanian
As and when we get the approval from China regulatory authorities for the China plant, we will supply to China also.
Question
Kunal Randeria: Right and any revenue number you would like to call out now, for the next three years?
Answer, s subramanian
S. Subramanian: No. This being the first year, we may not like to, but certainly I see a significant revenue coming up in two to three years’ time.
Question
Kunal Dhamesha: It's specific to gRevlimid right because there's patent expiry in let's say January, and everyone is given a particular market share, so is there a meaningful change that you expect early on in the year, let's say FY26 in terms of buying pattern, price erosion, volumes, or would it be more?
Answer, yugandhar puvvala
Yugandhar Puvvala: There are lot of things possible, Kunal. We don't know exactly how the market will shape up going forward into FY26. So, we are conscious of that and whatever volume what we have, we wanted to maximize the opportunity in Q4 and Q1. That's our thought process. Now, how things will shape up? I won't be in a position to clearly tell, but yes, the closer you go towards Jan 2026, things are going to change dynamically. Okay.
Answer, yugandhar puvvala
So, I don't know what others will do, but I know what I will do. Obviously, like we do have plans of continuing gRevlimid post the patent expiry starting from 1st Feb 2026 and it will be like any other generic, but we want to be there even the post [patent expiry]. 7 Aurobindo Pharma Limited 07 February 2025 Kunal Dhamesha: Sure.
Question
And one for Dr. Satakarni on the positive CHMP opinion that we have got on Filgrastim now. So, what's our launch plan? I believe we need to still get the marketing authorization approved and then we can launch. So, what's the timeline there and then how the pipeline is looking? Dr. Satakarni Makkapati: Good morning, Kunal.
Answer, satakarni makkapati
So, with respect to the positive opinions we have received from CHMP for Filgrastim and the long acting Filgrastim, I expect the marketing approvals in two months’ time. That's the usual timeline from receiving a positive opinion to completing the European Commission formalities for receiving a positive opinion [read it as ‘marketing approval’]. So, considering Dyrupeg or the pegylated Filgrastim gets approved in April an d Filgrastim slightly before that, we already have a bevacizumab biosimilar approval in UK. So, I think we will be starting our commercial supplies into the EU starting the quarter of July. So, in all likelihood, I expect a quarter and quarter and half o f revenue bookings to begin from this year. That's Part -1 of your question. Now, what was the Part -2?
Question
Kunal Dhamesha: Yeah. In terms of , how we have evolved, let's say quarter 2 to quarter 3, any clinical trial updates, etc that we have or the pipeline products? Dr. Satakarni Makkapati: So, we have four more products in the Phase 3 clinical trial.
Answer, satakarni makkapati
As I told you, I think last quarter the biosimilar to Xgeva and Prolia, which is a Denosumab biosimilar being tested in post-menopausal osteoporosis. We are on track to conclude the clinical study by May this year [2025], which means that we will have the clinical study report available with us by September [2025], and I hope to, if there are no further delays in gleaning the data, because this trial was completely conducted in 8 European countries and 65 sites, I expect the European filing to be in the October quarter and the U.S. filing to be in the Q4 of the next fiscal [FY26]. With respect to Omalizumab, which is a biosimilar to Xolair that is being tested in chronic spontaneous urticaria across the European sites in Caucasian public (patients), we are slightly delayed by about four to five months in closing out the (patient) recruitment. I think I talked about it last quarter, but what is important to note is, we made -up for a couple of months by increasing the number of sites in India, earlier India was not part of the recruitment plans which means that I'll still have a delay of three months in closing out the study. But I'm quietly confident that by the end of this year, the Omalizumab clinical study will be concluded as well. We already announced positive Phase 1 results with Omalizumab versus the European and the U.S. innovator product, I think last year.
Answer, satakarni makkapati
So, we are quite confident of closing out the Omalizumab clinical study by the end of the year, and Q4 filing, at least in Europe, still looks a possibility in the next fiscal. So, that's about the Omalizumab clinical study. The Bevacizumab clinical study has been going on for about 3 years now. We are inching towards the closure. I think in two quarters time we will conclude the recruitment phase and probably we will have a filing in Q1 -Q2 of the next fiscal, which means (in) FY26 -27 for Bevacizumab, but with the MHRA approval that we received for the Bevacizumab, we are talking to a few regulatory agencies in the emerging and the semi -regulated markets where we can position the dossier based on the MHRA approval alone. It's still very dyn amic in the 8 Aurobindo Pharma Limited 07 February 2025 way regulatory agencies look at how the product gets approved only based on Phase 1 and what is the process forward in approving it. So, if there are any approvals that I receive in emerging markets or semi-regulated markets, I'll let you know.
Answer, satakarni makkapati
The ophthalmic product is slow. We have an ophthalmic product in clinical trials. We are only at around 50% of the recruitment. So, I don't think we'll be able to complete the recruitment in 2025 as estimated before. I think we will be well into the second half of 2026 when we (will) conclude the Phase 3 clinical trial for the ophthalmic product. So, in the nutshell, except for the ophthalmic product, the pipeline is advancing fairly well and with approvals that we have received or the positive opinions that we have received, we are quite confident by 2026, we will be able to at least have six to seven products in the European and the semi-regulated markets. I hope that answers your question.
Show 17 more questions
Question
Anubhav Agarwal: Yeah. Hi, guys. Good morning to all . Two questions , one is for Yugandhar Sir. First on the injectable business, when I look at IQ VIA data, I do not see significant ramp up over last two or three quarters. The sales are just languishing. I understand that you guys been shipping this quarter had cut -off effect etc., b ut is it just a production problem where you say that you have 50% capacity utilization or there is unwillingness from the customer side to take product because of Eugia -3 situation?
Answer, yugandhar puvvala
Yugandhar Puvvala: No, it is mainly the production problem . Anubhav, I can tell you that with full confidence, it is that we are ramping up slowly and we don't want to rush anything and all our contracts and interest from the customers is very, very high and we are not in a position to meet the demand, but I do not want to rush anything just to meet the demand. I expect Q4 and Q1 of next year to be much better, but in terms of customer interest and all the contracts very much in place, absolutely no issue s. Anubhav Agarwal: And on the utilization, the reason utilization is low because CAPA progress is happening, does the facility still have lot of consultants over there?
Answer, yugandhar puvvala
Yugandhar Puvvala: No, consultants are no longer there, we just have transient consultants , we had a meeting with FDA and everything has been sorted out in October itself and we have transient consultants who are just two or three people working with us. Beyond that, we don't have any consultants , no longer available and no longer required, even as per FDA , and what we are doing is , because we have put in lot of CAPAs, we are recruiting more people to ensure that we meet up to our CAPAs and the recruitment process has taken time because in injectables getting good manpower is also not easy. So, now we have all the people in place, we have 95% of our requirement in terms of number of people , all have joined, they are under training from February onwards. Everybody is on the job, so that's why from March onwards , I expect the production ramp up to happen to the original levels. 9 Aurobindo Pharma Limited 07 February 2025 Anubhav Agarwal: That's very helpful.
Question
My second question is on the biosimilar front, and this is both for Subramanian Sir and Dr. Satakarni Sir. I'm just trying to understand, we have R&D of about ₹1,700 crore for the year, how much of that is going to biosimilars? That’s one part of the question. Secondly, how much freedom has Dr. Satakarni Sir got in terms of expense that he can do in the biosimilar front? What is the target and when does biosimilars as a business become profitable for Aurobindo? Dr. Satakarni Makkapati: Anubhav, I would take the question and ask Subbu to chime in with the numbers.
Answer, satakarni makkapati
The Part 1 of the question - I think we spend roughly about as a company 30%- 35% of our R&D into funding the development of biosimilars. Subbu will be able to give the exact numbers, but this is primarily driven by the Phase 3 clinical expenditure. So, out of the overall spend that we make on biosimilars, around 70% to 75% of the expenditure is incurred towards conducting the pivotal or Phase 3 efficacy studies. So, in the nutshell around 30% to 35% of the overall Aurobindo R&D spend is spent towards biosimilars. Now, to the Part 2 of the question. What was the Part 2 of the question? If you can repeat again.
Question
Anubhav Agarwal: Yes. Your part 2 of the question is, when does biosimilars as a division becomes profitable? Secondly, you are only using part of R&D as a resource right now, but Aurobindo has a very strong balance sheet also, so do you have the liberty to buy products also as your peers are doing versus or developing all yourself? Dr. Satakarni Makkapati: That's a very interesting question.
Answer, satakarni makkapati
I'm dabbling with those thoughts, Anubhav myself, because any company of the size of us, cannot do all biosimilars by ourselves. It requires enormity of resources allocation to conduct and develop these many products and clinical studies that we are doing. If you look at when we started out in 2018, July to now, we have conducted about I think 6 Phase 3 clinical trials, around 8 or 9 Phase 1 clinical trials, so that's the size of biosimilar studies at companies like Sandoz and the Mylan do. But having said that, any in-licensing opportunity that comes our way, that we believe will lend advantage to our businesses in Europe and U.S., we are open to those. We are scouting for a couple of opportunities, but we are more internally focused right now. In fact, our second wave of products or the third wave of products that you may call them post 2028, most of the product pipeline is now in a decent development stage where we may begin the Phase 1 and Phase 3 clinical studies starting end of 2025 and early 2026. So, any products that we miss out from our portfolio, which we think will make a significant addition to our commercial base in regulated or semi-regulated markets, we are open to in-licensing opportunities.
Answer, satakarni makkapati
There is enough freedom to go out and scout for products and in-license them when and if required, Anubhav, but right now, we covered most of the important products that we think will position us both in Oncology, Dermatology, and the Immunology segments, so Dermatology is part of Immunology. So, we are pretty confident with the broader pipeline that we (are) already have (ing). To answer the next part of your question, when we think as a business, we will be breaking even. As I told you, 2028 to 2030 will be the inflection point of this business. You can already see that we have 3 products which are approved, 2 with a positive opinion in Europe, 1 in UK, and we are expecting one more this year and with Denosumab, Omalizumab, and one more 10 Aurobindo Pharma Limited 07 February 2025 in the next year, we expect at least 7 products to be commercialized fully by the year 2027 (28). And [by] 2028 to 2030, will build in a good revenue base for us, where I think the company takes off by itself. So, we are enthusiastic about the progress that we are making and we are very sure footed in our investment and very prudent about the product choices we are making in the biosimilar segment, Anubhav.
Question
Yash Darak: Yeah. Can you please state operationalisation status of Pen-G and at what percent of utilization are we currently working, and how do we see it progressing forward?
Answer, s subramanian
S. Subramanian: Yash, the question of talking about utilization is secondary. The first thing what we have done is, how do we improve the yields etc., which we have been working and we have been fairly successful after the slight modifications etc., we have done and we have been seeing very good really results and in next two months we will continue that and the ramp up will take place starting April. It is not the question of capacity utilization. You need to achieve the desired yield level , that’s what we are working on.
Question
Yash Darak: So do we expect the sales to ramp up from April?
Answer, s subramanian
S. Subramanian: I think that is what we are planning. In fact, touch wood, everything goes well, March also, we may be able to do that, but let's take it as April. Yash Darak: Okay and secondly, Sir there was a PLI scheme which was introduced in the budget with amounting to ₹2,445 crores, are we expecting to benefit from that?
Question
Surya Patra: Thanks for the opportunity, Sir. My first question is on the respiratory product opportunity. What you have talked in the opening remarks also, so we know that there has been around 14 odd products that has already been there in the various stages of development, and I think the last quarter that we have also collaborated with one of the U.S. company to develop even a basket more. So, could you give some sense of what is the progress on those products? What kind of product that we are talking about there, and by when that we will really start seeing revenue contribution coming from that side?
Answer, swami iyer
Swami Iyer: I can take this question Subbu. Swami Iyer: Primarily we're talking about the MDI and DPI. Yes, you're right. We had announced last quarter about tie up with an international firm. Now, apart from that, we have a good R&D setup, and are developing few products which are in the various stages, in some cases the filings have been done (at least 2 of them) and few more are in advanced stage. We believe that these are good products with fairly good dollar values and we anticipate some of these products to come in late in the FY26 or maybe in the mid first half of FY27 and then from there we would have regular products coming in.
Question
Surya Patra: Okay. And this collaboration, if you can just add some color on this?
Answer, swami iyer
Swami Iyer: We have tied up with the firm for the development of the product and we'll be launching it. This is a little medium-term, it’s not short-term. Obviously, the development takes some time. We believe that this product has got a large market and we also feel confident that we should be able to launch it without any IP constraints. We have taken care of that we believe and this is a large company that we have tied up with and there is another party which is helping in the development too. 12 Aurobindo Pharma Limited 07 February 2025 Surya Patra: My second question is on the U.S. business front.
Question
I think we have seen there is a kind of uptick in the branded Oncology business beyond the kind of a run rate of a US$ 25 to US$ 30 million, what it is been indicated earlier and similarly, even though OTC also has seen a kind of sequential as well as YoY uptick, and on the Eugia front, what around sequentially in the last two quarters $20 million kind of sequential decline that we are witnessing, so is it entirely because of that Eugia facility issue? So, if you can address these 3 segments?
Answer, swami iyer
Swami Iyer: Sure. Eugia part, I would leave it to Yugandhar to handle. Other than Eugia , I can talk about R x oral solids and the OTC. So, Yugandhar , would you like to take up Eugia first?
Answer, yugandhar puvvala
Yugandhar Puvvala: Yeah, I think I already clarified that, like last two quarters have been mainly related to supply related issues and, per quarter we were impacted by around US$10 million and I expect from this quarter onwards we'll be back to normal run rate. It is mainly driven by the supply challenges, not related to the demand challenges. So, that I hope I've clarified multiple times. I hope that addresses your question.
Question
Surya Patra: Thank you, Sir.
Answer, swami iyer
Swami Iyer: Okay. So, I'll talk about the oral solids and OTC . On both sides, we had a very good quarter with all round progress. There's been steady progress and we believe that this will continue going forward and we are focused on sustainable long -term based business and we are making more efforts to try and achieve that goal. We have a robust set of commercial products already in important, in almost all therapeutic segments and we are rapidly moving to a future with much more diversified portfolio. You know, you had mentioned about the MDI, the inhalation product. Similarly, we have in transdermal area and we are trying to diversify into different presentation, more value-added, value creating product, and we also amassed expansive pipeline with great potential to sustain and you know, our goal is to be the global generic powerhouse which we are to an extent at this point, but we expect to continue being there and doing better.
Question
Surya Patra: Sir, with your permission, can I just ask one more question, Sir? This is about AuroPeptides. Now, Dr. Satakarni Sir, can you give some sense about what is our preparedness about the GLP -1 and also the kind of a competitive edge that we would be having because here most of the competing peers are indicating about integrated operation there. 13 Aurobindo Pharma Limited 07 February 2025 Dr. Satakarni Makkapati: Hello.
Answer, satakarni makkapati
AuroPeptides is into the manufacturing of APIs. So, with respect to GLP-1s, right now, we have 1 GLP-1 peptide, active DMF, the other one we are going to file the DMF this year and we are investing in development of another GLP-1 Peptide. Anything on the finished product, you should talk to Yugandhar. He'll be able to answer that.
Question
Surya Patra: Yeah. Yes, please.
Answer, yugandhar puvvala
Yugandhar Puvvala: Yeah, Surya. We have entire GLP product range. In fact, at our Vizag plant, we have a significant capacity cartridge line where we'll be filing all the GLP-1 products, Liraglutide, Semaglutide, Teriparatide, okay. Everything in the GLP pipeline is covered by us and we will be filing from our new Vizag plant.
Question
Surya Patra: Okay. And even the device is our captive?
Answer, yugandhar puvvala
Yugandhar Puvvala: Device is always outside , because either it is from B D or from somebody else like the device manufacturing company, but device assembly, along with the medicine happens in our plant. But device per say is always from outside companies.
Question
Surya Patra: Thank you, Sir.
Answer, v muralidharan
V. Muralidharan: Yeah. Hi, good morning. This is Muralidharan. Thank you for raising this question. Yes, Europe has been contributing close to 27% of the global revenues for Aurobindo. Currently, we are doing this based on the wide portfolio of the products and efficient supply chain and increased supplies originating mainly from India and faster turnaround of the products at our quality lab, mainly at Malta. Some of these factors and a well-oiled, frontend infrastructure and machinery, commercial infrastructure.
Answer, v muralidharan
So, all these are working in our favor at this moment. Also, we are availing the market opportunities in a big way and, other mechanisms, standard ones like the demand for testing and timely supplies. All these are contributing to this robust performance, and we expect the momentum to continue in the coming year and quarters ahead. And having said that, we are looking for further launches that will happen from Eugia space as well as biosimilar space and that will further take us to the higher levels. Bino: Got it. But most of these things would have been a work in progress over the years, but what has really happened this year that suddenly there is a growth spurt ? 14 Aurobindo Pharma Limited 07 February 2025 V. Muralidharan: No, you're right in it, but at the same time, over the last several quarters or last couple of years, we were fine tuning.
Answer, v muralidharan
We were missing out on couple of these aspects to happen in the right tandem and definitely things are happening at the right perspective as of now. Bino: Got it, got it.
Answer, yugandhar puvvala
Yugandhar Puvvala: Just to add like there can be supply challenges from a lot of companies and we are in a position to, take in fact like even Eugia has been growing at a rate of 20% in Europe. So, we don't want to comment on other organizations, but yes, we have been seeing supply challenges from multiple companies and we are in a position to fulfil the demand wherever the gaps are. Bino: Understood. Thank you. My second question now is about India. So, you have this Trastuzumab approval already. How do you plan to sell it?
Answer, satakarni makkapati
So, we have an approval by the CDSCO for Trastuzumab. We are putting together our domestic marketing and sales team, which will kick in probably by the end of this year, but until then, the first two quarters the sales will be through co -marketing partners. But going forward, in the domestic market, we are going to add a good sales team essentially to take our biosimilars to the patients and the prescribers. So, that's the strategy that you will see evolving in the next two to four quarters time. Bino: Understood . And the sales team is only for biosimilars , you won't have any other products ? Dr. Satakarni Makkapati: For the biosimilars, we are having a separate sales team because they specialize in branding it, and importantly, there is a lot of network that is required to put forward biosimilars to the prescribers convincingly.
Answer, satakarni makkapati
But having said that, any support to medication or concomitant medication that goes with biosimilars will also be marketed by the same team. Bino: Understood and GLP-1 plans? Dr. Satakarni Makkapati: For India, GLP -1, we have our plans.
Answer, satakarni makkapati
We are talking to the agencies to see what sort of study requirements must be met, but you will see some announcement from me in the next two quarters time about our strategy in the domestic markets of GLP -1s. Bino: Sure. Thank you.
Question
Tarang Agarwal: Okay. On Eugia Sir, you said that Eugia utilisation is currently at about 50% for Eugia-3, does this also include the expanded capacity of Eugia-3?
Answer, yugandhar puvvala
Yugandhar Puvvala: No, Tarang. It's actually like expanded capacity is line 13, line 14, and that I'm not even considering. I'm talking about the existing capacity of because those lines are not approved so far. So, I don't consider them as a capacity available. But up to whatever lines we have, we have been using around 70%-75% in the past. Right now, we were using around 50%, so like we are confident that we will come back to our original levels of 65 %-70% capacity utilization of the previous capacity. As and when the new line gets approved, that will be an additional capacity.
Question
Tarang Agarwal: Sir, so practically, what is the utilization that the business can go through number 1. Number 2, between line 13, line 14 and the Vizag plant, when do you expect the approvals to come through and if one were to consider line 13 and line 14 capacity to be theoretically available and Vizag to be theoretically available as on date, what would be the utilization for the injectables business?
Answer, yugandhar puvvala
Yugandhar Puvvala: Vizag is still in nascent stages because we got approvals for terminally sterile lines. Now, we will be going for the aseptic lines approval that audit is due and then we will be adding different varieties of things in Vizag, the cartridge lines will be all exclusive only for Vizag and there is a PFS, BFS all those lines what we will be adding. So, between Eugia-3 and Vizag facility, we will have significant capacity to take care up to FY30 in terms of the capacity available for the business and our business growth plans.
Question
Tarang Agarwal: Got it. Thank you, Sir. And the last question on Europe, Sir you know fantastic execution of the last three years I would say . Euro revenues have been growing at a range of anywhere between 10% to 13%. If I look at it from a nine monthly basis, just wanted to get a pulse of, you know, how are the margins on this business because as we understand at some point of time the margins were low middle digits and there was an inflection point that the business was looking for those margins to really inch up, so comment there would be helpful and how should we see this €235 million run rate going forward on a quarterly basis?
Answer, v muralidharan
V. Muralidharan: Yeah, Tarang, thank you for this. Yeah, I mean on the margin side as well as we are very constantly looking at the opportunity sales to be availed, definitely we are clocking better margins . Of course, the specific numbers, Subbu will be able to comment at the appropriate time and coming to the run rate of €230 million plus is , we are confident of sustaining this in the coming period as well. If I have to take January as a benchmark, 16 Aurobindo Pharma Limited 07 February 2025 definitely we are on it, but yes, we will announce the full quarter results as we come to the end of the financial year.
Question
Neha Manpuria: Yeah. Thanks for taking my question. Swami Sir, you know the 2 billion units in China that will free up capacity probably in the India manufacturing for the U.S. market and the fact that we're also adding capacity in Raleigh, etc., you know how much additional capacity would you have for the U.S. market going into next year and how confident are we of being able to actually capitalize on that without necessarily putting pressure on the market given how large we've become in the U.S.?
Answer, swami iyer
Swami Iyer: Thanks , Neha . I'll take the second question first , on the ability to sell the volume that's being generated. We are happy to take on more volumes. We have a good market as you know we are number 1 in years in terms of prescription, we have a large base, but we believe that we have a s cope to grow. We are today 11% market share. We think that th ere is scope to grow given our background, given our infrastructure in India. Now, the North Carolina facility is nothing to do with the oral solids.
Answer, swami iyer
It’s a differentiated presentation. One is the topical, transdermal and the inhalation. So, that we don't have to count towards the normal 2 billion odd we are selling here. As far as China is concerned, China is not only for US , it's also for other market so, we are looking for contribution from China in terms of volume and even our own units , I think they are adding balancing equipment. They are able to ramp up. We could see some more volume surge in the next few quarters and we'll be able to take it on. We don't see a situation at this point where we would have these facilities being underutilized except for pockets.
Questions about this call
- When was the Aurobindo Pharma Q3 FY25 earnings call transcript filed?
- Aurobindo Pharma filed the transcript with the exchange on 13 Feb 2025. This page is built from that transcript.
- What does this page list?
- 74 statements from the transcript across 8 topics, 46 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 27 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.